{"id":543880,"date":"2021-05-19T22:40:01","date_gmt":"2021-05-19T22:40:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=543880"},"modified":"2021-05-19T22:40:01","modified_gmt":"2021-05-19T22:40:01","slug":"sezary-syndrome-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-trillium-therapeutics-4sc-innate-pharma-seagen-and-many-others","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/sezary-syndrome-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-trillium-therapeutics-4sc-innate-pharma-seagen-and-many-others_543880.html","title":{"rendered":"Sezary Syndrome Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Trillium Therapeutics, 4SC, Innate Pharma, Seagen and Many Others"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1621309095.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Sezary Syndrome Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Trillium Therapeutics, 4SC, Innate Pharma, Seagen and Many Others\" src=\"https:\/\/www.abnewswire.com\/uploads\/1621309095.jpeg\" alt=\"Sezary Syndrome Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Trillium Therapeutics, 4SC, Innate Pharma, Seagen and Many Others\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Sezary Syndrome Pipeline<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\"><strong>Sezary Syndrome<\/strong> is an aggressive form of cutaneous T-cell lymphoma which is a group of disorders that occur when T-cells (a type of white blood cell) become cancerous and affect the skin. It is characterized by a widespread red rash that may cover most of the body, the presence of cancerous T cells (called Sezary cells) in the blood, and abnormally enlarged lymph nodes.<\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s,&nbsp;<strong>&ldquo;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/sezary-syndrome-ss-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Sezary Syndrome Pipeline<\/a> Insight, 2021,&rdquo;&nbsp;<\/strong>report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Sezary Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of <\/strong><strong>Sezary Syndrome Companies are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Trillium Therapeutics<\/li>\n<li>4SC<\/li>\n<li>Innate Pharma<\/li>\n<li>Seagen<\/li>\n<li>Elorac<\/li>\n<li>SciTech Development<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for free Sample Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/sezary-syndrome-ss-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/sezary-syndrome-ss-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>DelveInsight&rsquo;s <\/strong><strong>Sezary Syndrome report covers around 10+ products under different phases of clinical development like<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Late-stage products (Phase III and<\/li>\n<li>Mid-stage products (Phase II and<\/li>\n<li>Early-stage products (Phase I\/II and Phase I) along with the details of<\/li>\n<li>Pre-clinical and Discovery stage candidates<\/li>\n<li>Discontinued &amp; Inactive candidates<\/li>\n<li>Route of Administration<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of <\/strong><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/sezary-syndrome-ss-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Sezary Syndrome Therapies<\/a> are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>TTI-621<\/li>\n<li>Resminostat<\/li>\n<li>Lacutamab<\/li>\n<li>Brentuximab vedotin<\/li>\n<li>Naloxone Hydrochloride<\/li>\n<li>Fenretinide<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for free Sample Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/sezary-syndrome-ss-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/sezary-syndrome-ss-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Current <\/strong><strong>Sezary Syndrome Treatment Scenario and Sezary Syndrome Emerging Therapies:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>How many companies are developing Sezary Syndrome drugs?<\/li>\n<li>How many Sezary Syndrome drugs are developed by each company?<\/li>\n<li>How many emerging drugs are in mid-stage, and late-stage of development for Sezary Syndrome?<\/li>\n<li>What are the key collaborations (Industry&ndash;Industry, Industry&ndash;Academia), Mergers and acquisitions, licensing activities related to the Sezary Syndrome therapeutics?<\/li>\n<li>What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?<\/li>\n<li>What are the clinical studies going on for Sezary Syndrome and their status?<\/li>\n<li>What are the key designations that have been granted to the emerging drugs?<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Also have a look at &#8211; Sezary Syndrome Market Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/sezary-syndrome-ss-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/report-store\/sezary-syndrome-ss-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents:<\/strong><\/p>\n<p style=\"text-align: justify;\">Introduction<\/p>\n<p style=\"text-align: justify;\">Executive Summary<\/p>\n<p style=\"text-align: justify;\">Sezary syndrome: Overview<\/p>\n<p style=\"text-align: justify;\">Pipeline Therapeutics<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">Sezary syndrome&ndash; DelveInsight&rsquo;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\">In-depth Commercial Assessment<\/p>\n<p style=\"text-align: justify;\">&bull; Sezary syndrome companies&rsquo; collaborations, Licensing, Acquisition -Deal Value Trends<\/p>\n<p style=\"text-align: justify;\">Sezary syndrome Collaboration Deals<\/p>\n<p style=\"text-align: justify;\">Late Stage Products (Phase III)<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">Naloxone Hydrochloride: Elorac<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Mid Stage Products (Phase II)<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">Lacutamab: Innate Pharma<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Early Stage Products (Phase I)<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">Fenretinide: SciTech Development<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Preclinical and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">Drug Name: Company Name<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Inactive Products<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">Sezary syndrome Key Companies<\/p>\n<p style=\"text-align: justify;\">Sezary syndrome Key Products<\/p>\n<p style=\"text-align: justify;\">Sezary syndrome- Unmet Needs<\/p>\n<p style=\"text-align: justify;\">Sezary syndrome- Market Drivers and Barriers<\/p>\n<p style=\"text-align: justify;\">Sezary syndrome- Future Perspectives and Conclusion<\/p>\n<p style=\"text-align: justify;\">Sezary syndrome Analyst Views<\/p>\n<p style=\"text-align: justify;\">Sezary syndrome Key Companies<\/p>\n<p style=\"text-align: justify;\">Appendix<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Detailed TOC: https:\/\/www.delveinsight.com\/sample-request\/sezary-syndrome-ss-pipeline-insight<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About&nbsp;<\/strong><strong>DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.&nbsp; Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform&nbsp;PharmDelve.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=sezary-syndrome-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-trillium-therapeutics-4sc-innate-pharma-seagen-and-many-others\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/sezary-syndrome-ss-pipeline-insight\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/sezary-syndrome-ss-pipeline-insight<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/sezary-syndrome-ss-pipeline-insight\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=sezary-syndrome-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-trillium-therapeutics-4sc-innate-pharma-seagen-and-many-others\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sezary Syndrome Pipeline Sezary Syndrome is an aggressive form of cutaneous T-cell lymphoma which is a group of disorders that occur when T-cells (a type of white blood cell) become cancerous and affect the skin. It is characterized by a &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/sezary-syndrome-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-trillium-therapeutics-4sc-innate-pharma-seagen-and-many-others_543880.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-543880","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/543880","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=543880"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/543880\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=543880"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=543880"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=543880"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}